ArticleCureus2026
Prognostic Significance of Her-2/Neu and Ki-67 Expression in Gallbladder Carcinoma: A Clinicopathological Study Across Resectable and Advanced Stages.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gallbladder carcinomas (GBC) are aggressive biliary tract malignancies, which, as a result of advanced stage at presentation and poor outcome with standard treatment, lead to significant mortality. There is an unmet need to find prognostic and predictive biomarkers in GBC that can guide treatment escalation. Hence, we aimed to study the expression of Her-2/Neu and Ki-67 by immunohistochemistry (IHC) in GBC and their correlation with clinicopathological parameters and survival outcomes. Method This retrospective study was conducted at a tertiary cancer center in North India over a period of 20 months, during which GBC cases were retrieved, and IHC for Her-2/Neu and Ki-67 was performed and analyzed. Result A total of 133 cases of GBC were analyzed, with a median age of 54.1 years, comprising 93 females (70%). Adenocarcinomas were the most common histology with 125 cases (94%), and most cases (n=54, 40.6%) were moderately differentiated. Positive Her-2/Neu expression was found in 30 cases (22.6%), with a significant loss of Her-2/Neu expression as tumor grade increased (p-value <0.05). The Ki-67 proliferation index showed a significant association with increasing tumor grade (p-value <0.05). A significant correlation was noted between higher tumor grades 2/3 and metastatic/inoperable disease, liver, and lymph node metastasis (p-value <0.05). Median overall survival (OS) was 6 months in resectable and three months in metastatic disease. However, no significant association was noted between OS and Her-2/Neu positivity, grade, or Ki-67 in metastatic/inoperable disease. In resectable GBC, median OS was significantly better in grade 1 cancers than in higher-grade 2/3 cancers by 12 months (p-value <0.05), whereas a trend towards better OS was seen in cancers with Ki-67 less than 50. Her-2/Neu positivity made no difference in OS for resectable cancers. Conclusion Her-2/Neu positivity declines with poor tumor differentiation, without any effect on prognosis in resectable GBC. The Ki67 index, along with tumor grading, offers potential as a predictive and prognostic marker in resectable GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.